COVID-19 门诊患者症状缓解的遗传学研究。
Genetics of symptom remission in outpatients with COVID-19.
机构信息
Montreal Heart Institute, 5000 Belanger Street, Montreal, H1T 1C8, Canada.
Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada.
出版信息
Sci Rep. 2021 May 25;11(1):10847. doi: 10.1038/s41598-021-90365-6.
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 × 10) in interaction with colchicine (P = 1.19 × 10) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.
我们对 COLCORONA 临床试验中的 1723 名至少有一个疾病严重程度风险因素的门诊患者的 COVID-19 症状缓解时间进行了全基因组关联研究。我们在靠近利钠肽受体 3 基因（NPR3）的 5p13.3 处（rs1173773；P=4.94×10）发现了一个显著关联。在研究的第 15 天，分别有 0、1 或 2 个效应等位基因的参与者中，有 44%、54%和 59%的人症状缓解。在 851 名未接受秋水仙碱（安慰剂）治疗的参与者中，在与秋水仙碱（P=1.19×10）相互作用的 9q33.1 处（rs62575331；P=2.95×10）存在显著关联，但对住院风险没有影响，突出了一个可能共享的机制途径。在研究的第 15 天，分别有 0、1 或 2 个效应等位基因的参与者中，有 46%、62%和 64%的人症状缓解。这些发现需要进一步复制，可能有助于对 COVID-19 症状缓解的生物学理解。
Zotero 插件